135 related articles for article (PubMed ID: 36745506)
21. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Hawash MM; Kahraman DC; Eren F; Cetin Atalay R; Baytas SN
Eur J Med Chem; 2017 Mar; 129():12-26. PubMed ID: 28219046
[TBL] [Abstract][Full Text] [Related]
22. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
23. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Fan X; Deng J; Shi T; Wen H; Li J; Liang Z; Lei F; Liu D; Zhang H; Liang Y; Hao X; Wang Z
Bioorg Chem; 2021 Sep; 114():105154. PubMed ID: 34378540
[TBL] [Abstract][Full Text] [Related]
26. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma.
Yan JX; Li QH; Li TZ; Huang ZY; Ma YB; Chen JJ
Drug Dev Res; 2023 Sep; 84(6):1285-1298. PubMed ID: 37345274
[TBL] [Abstract][Full Text] [Related]
28. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
[TBL] [Abstract][Full Text] [Related]
30. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Yao X; Zhao CR; Yin H; Wang K; Gao JJ
Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, toxicity and antitumor activity of cobalt carbonyl complexes targeting hepatocellular carcinoma.
Li J; Zhang J; Zhang Q; Wang Y; Bai Z; Zhao Q; He D; Wang Z; Zhang J; Chen Y
Bioorg Med Chem; 2019 Oct; 27(20):115071. PubMed ID: 31472989
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
34. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
35. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
36. Design and Synthesis of Analogues of Marine Natural Product Galaxamide, an N-methylated Cyclic Pentapeptide, as Potential Anti-Tumor Agent in Vitro.
Lunagariya J; Zhong S; Chen J; Bai D; Bhadja P; Long W; Liao X; Tang X; Xu S
Mar Drugs; 2016 Sep; 14(9):. PubMed ID: 27598177
[TBL] [Abstract][Full Text] [Related]
37. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
38. Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Yang Y; Qin SK; Wu Q; Wang ZS; Zheng RS; Tong XH; Liu H; Tao L; He XD
Oncol Rep; 2014 Feb; 31(2):540-50. PubMed ID: 24317203
[TBL] [Abstract][Full Text] [Related]
39. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
40. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]